Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Amino acid sequence disclosed in whole or in part; or...
Reexamination Certificate
2011-06-14
2011-06-14
Mosher, Mary E (Department: 1648)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Amino acid sequence disclosed in whole or in part; or...
C424S193100, C424S196110, C435S069100, C536S023400, C536S023510, C536S023720
Reexamination Certificate
active
07959924
ABSTRACT:
The present invention is in the fields of medicine, public health, immunology, molecular biology and virology. The present invention provides, inter alia, a composition comprising a virus-like particle (VLP) and at least one antigen, wherein said antigen is a GIP protein or a GIP fragment linked to the VLP respectively.The invention also provides a method for producing the aforesaid composition. The compositions of this invention are useful in the production of vaccines, in particular, for the prevention and/or treatment of obesity and hereby, in particular, by inducing efficient immune responses, in particular antibody responses. Furthermore, the compositions of the invention are particularly useful to efficiently induce self-specific immune responses within the indicated context. Accordingly, the invention further provides for methods of treating and/or preventing obesity and other conditions.
REFERENCES:
patent: 4722840 (1988-02-01), Valenzuela et al.
patent: 4918166 (1990-04-01), Kingsman et al.
patent: 5143726 (1992-09-01), Thornton et al.
patent: 5580859 (1996-12-01), Felgner et al.
patent: 5698424 (1997-12-01), Mastico et al.
patent: 5928647 (1999-07-01), Rock
patent: 6004763 (1999-12-01), Gengoux et al.
patent: 6054312 (2000-04-01), Larocca et al.
patent: 6159728 (2000-12-01), Stockley et al.
patent: 6548651 (2003-04-01), Nielsen et al.
patent: 7572451 (2009-08-01), Bachmann et al.
patent: 2002/0064533 (2002-05-01), Murray
patent: 2002/0081295 (2002-06-01), Schiller et al.
patent: 2002/0193565 (2002-12-01), Stanley et al.
patent: 2003/0054010 (2003-03-01), Sebbel et al.
patent: 2003/0175290 (2003-09-01), Renner et al.
patent: 2004/0076611 (2004-04-01), Bachmann et al.
patent: 2004/0076645 (2004-04-01), Bachmann et al.
patent: 2005/0191317 (2005-09-01), Bachmann et al.
patent: 2005/0272652 (2005-12-01), Gault et al.
patent: 2006/0121468 (2006-06-01), Allnutt et al.
patent: 0 479 210 (1992-04-01), None
patent: 1 171 465 (2002-01-01), None
patent: WO 99/08708 (1999-02-01), None
patent: WO 99/57289 (1999-11-01), None
patent: WO 00/20592 (2000-04-01), None
patent: WO 00/23955 (2000-04-01), None
patent: WO 00/32227 (2000-06-01), None
patent: WO 00/58360 (2000-10-01), None
patent: WO 01/85208 (2001-11-01), None
patent: WO 02/10195 (2002-02-01), None
patent: WO 02/094124 (2002-11-01), None
patent: WO 03/030946 (2003-04-01), None
patent: WO 03/060071 (2003-07-01), None
patent: WO 03/103697 (2003-12-01), None
patent: WO 2004/003143 (2004-01-01), None
patent: WO 2004/004761 (2004-01-01), None
patent: WO 2004/007538 (2004-01-01), None
patent: WO 2004/009116 (2004-01-01), None
patent: WO 2004/009124 (2004-01-01), None
patent: WO 2005/082928 (2005-09-01), None
patent: WO 2006/032674 (2006-03-01), None
Zorrilla, et al. Vaccination against weight gain. PNAS. 2006; 103(35): 13226-13231.
Fulurija, et al. Vaccination against GIP for the Treatment of Obesity. PLoS One. 2008; 3(9):e3163,1-11.
Baba, A.S.H., et al., “Effects of gastric inhibitory polypeptide, somatostatin and epidermal growth factor on lipogenesis in ovine adipose explants,”Comp. Biochem. Physiol. B. Biochem. Mol. Biol. 127: 173-82, Elsevier Science Inc. (2000).
Bachmann, M.F., Zinkernagel, R.M., “The influence of virus structure on antibody responses and virus serotype formation,”Immunol. Today 17: 553-8, Elsevier Science Publishers (1996).
Ballinger, A., “Gastric inhibitory polypeptide links overnutrition to obesity,”Gut52: 319-20, British Medical Ass. (Mar. 2003).
Brown, J.C., et al., “Preparation of highly active enterogastrone,”Can. J. Physiol. Pharmacol. 47: 113-114, NRC Research Paper (1969).
Brown, W.L., et al., “RNA bacteriophage capsid-mediated drug delivery and epitope presentation,”Intervirology 45: 371-80, Karger (2002).
Brubaker, P.L. and Drucker, D.J. “Structure-Function of the Glucagon Receptor Family of G Protein-Coupled Receptors: The Glucagon, GIP, GLP-1, and GLP-2 Receptors,”Recept. Channels 8: 179-188, Taylor & Francis (2002).
Chackerian, B., et al., “Induction of autoantibodies to mouse CCR5 with recombinant papillomavirus particles,”Proc. Natl. Acad. Sci. USA 96: 2373-2378, National Academy of Sciences (1999).
Creutzfeldt, W. and Ebert, R., “New developments in the incretin concept,”Diabetologia28: 565-573, Springer-Verlag (1985).
D'Alessio, D.A., et al., “Elimination of the Action of Glucagon-like Peptide 1 Causes an Impairment of Glucose Tolerance after Nutrient Ingestion by Healthy Baboons,”J. Clin. Invest. 97: 133-138, American Society for Clinical Investigation (1996).
Drucker, D.J., “Enhancing Incretin Action for the Treatment of Type 2 Diabetes,”Diabetes Care 26: 2929-2940, The American Diabetes Association (Oct. 2003).
Dupre, J., et al., “Stimulation of Insulin Secretion by Gastric Inhibitory Polypeptide in Man,”J. Clin. Endocrinol. Metab. 37: 826-828, Endocrine Society (1973).
Ebert, R. and Creutzfeldt, W., “Influence of Gastric Inhibitory Polypeptide Antiserum on Glucose-Induced Insulin Secretion in Rats,”Endocrinology 111: 1601-1606, The Endocrine Society (1982).
Elliott, R.M., et al., “Glucagon-like peptide-1 (7-36)amide and glucose-dependent insulinotropic polypeptide secretion in response to nutrient ingestion in man: acute post-prandial and 24-h secretion patterns,”J. Endocrinol. 138: 159-166, Journal of Endocrinology Ltd (1993).
Fehr, T., et al., “T cell-independent type I antibody response against B cell epitopes expressed repetitively on recombinant virus particles,”Proc. Natl. Acad. Sci. USA, 95: 9477-81, National Academy of Sciences (1998).
Fulurija, A., et al., “Vaccination against GIP for the Treatment of Obesity,”PLoS ONE 3: e3163, Public Library of Science (Sep. 2008).
Gatto, D., et al., “Rapid Response of Marginal Zone B Cells to Viral Particles,”J. Immunol. 173: 4308-4316, The American Association of Immunologists, Inc. (Oct. 2004).
Gault, V.A., et al., “Characterization of the Cellular and Metabolic Effects of a Novel Enzyme-Resistant Antagonist of Glucose-Dependent Insulinotropic Polypeptide,”Biochem. Biophys. Res. Commun. 290: 1420-1426, Elsevier Science (2002).
Gault, V.A., et al., “Chemical Ablation of Gastric Inhibitory Polypeptide Receptor Action by Daily (Pro3) GIP Administration Improves Glucose Tolerance and Ameliorates Insulin Resistance and Abnormalities of Islet Structure in Obesity-Related Diabetes,”Diabetes 54: 2436-2446, American Diabetes Association (Aug. 2005).
Gault, V.A., et al., “DPP IV resistance and insulin releasing activity of a novel di-substituted analogue of glucose-dependent insulinotropic polypeptide, (Ser2-Asp13)GIP,”Cell Biol. Int. 27:41-46, Elsevier Science Ltd. (Jan. 2003).
Gault, V.A., et al., “Glucose-dependent insulinotropic polypeptide (GIP): anti-diabetic and anti-obesity potential?,”Neuropeptides 37: 253-63, Elsevier Ltd. (Oct. 2003).
Gault, V.A., et al., “Glucose-dependent insulinotropic polypeptide analogues and their therapeutic potential for the treatment of obesity-diabetes,”Biochem. Biophys. Res. Commun. 308: 207-213, Elsevier Inc. (Aug. 2003).
Gelling, R.W., et al., “GIP6-30amidecontains the high affinity binding region of GIP and is a potent inhibitor of GIP1-42action in vitro,”Regul. Pept. 69: 151-154, Elsevier Science (1997).
Hinke, S.A., et al., “Dipeptidyl Peptidase IV-Resistant [D-Ala2]Glucose-Dependent Insulinotropic Polypeptide (GIP) Improves Glucose Tolerance in Normal and Obese Diabetic Rats,”Diabetes 51: 652-661, American Diabetes Association (2002).
Hinke, S.A., et al., “Identification of a bioactive domain in the amino-terminus of glucose-dependent insulinotropic polypeptide (GIP),”Biochim. Biophys. Acta. 1547: 143-155, Elsevier Science B.V. (2001).
Hinke, S.A., et al., “In depth analysis of the N-terminal bioactive domain of gastric inhibitory polypeptide,”Life Sci. 7
Bachmann Martin F.
Fulurija Alma
Saudan Philippe
Cytos Biotechnology AG
Mosher Mary E
Snyder Stuart W
Sterne Kessler Goldstein & Fox P.L.L.C.
LandOfFree
Gastric inhibitory polypeptide (GIP) antigen arrays and uses... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Gastric inhibitory polypeptide (GIP) antigen arrays and uses..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Gastric inhibitory polypeptide (GIP) antigen arrays and uses... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2731326